Pediatric Dosing of Ganciclovir and Valganciclovir: How Model-Based Simulations Can Prevent Underexposure and Potential Treatment Failure.

A clear trend to increasing exposure with increasing age is observed with BW‐based dosing ( Figure 1 b ), with a larger fraction of patients of AUC 0–24 below 40 μg ∙ hour/mL in younger pediatric patients (96% in < 4 months and in 4 months to 2 years) than in older pediatric patients (71% in 12–16 years).

also in 19,460 other papers